Intravesical therapy of superficial bladder cancer

被引：34

作者：

Malmström, PU ^{[1
]}

机构：

[1] Univ Uppsala Hosp, Akad Sjukhuset, Dept Urol, SE-75185 Uppsala, Sweden

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2003年 / 47卷 / 02期

关键词：

bladder carcinoma; intravesical therapy; Bacillus Calmette-Guerin;

D O I：

10.1016/S1040-8428(03)00075-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of treatment of superficial bladder cancer with intravesical therapy is threefold: (1) Eradicate existing disease. (2) Prevention of recurrence. (3) Prevention of tumor progression. The prognostic factors allow differentiation in different risk groups and this is useful in planning treatment. Studies on pharmacokinetics have proved the efficacy of optimized drug delivery. Comparing resection with and without intravesical chemotherapy a short term approximately 15% decrease in tumor recurrence with chemotherapy can be obtained but no effect on progression was proven. No agent has proved more effective than the other. Single, early instillation of chemotherapy has proven effective but the role of maintenance therapy has been controversial. Immunotherapy in the form of Bacillus Calmette-Guerin generally have proven more efficacious than chemotherapy. The results in comparison to mitomycin C have not been as conclusive. Several new approaches are explored to improve the efficacy of this therapy. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：109 / 126

页数：18

共 138 条

[1] A CONTROLLED TRIAL OF SINGLE DOSE INTRAVESICAL ADRIAMYCIN IN SUPERFICIAL BLADDER-TUMORS [J].

ABRAMS, PH ;

CHOA, RG ;

GACHES, CGC ;

ASHKEN, MH ;

GREEN, NA .

BRITISH JOURNAL OF UROLOGY, 1981, 53 (06) :585-587

[2] LONG-TERM RESULTS OF INTRAVESICAL CHEMOPROPHYLAXIS OF SUPERFICIAL BLADDER-CANCER - EXPERIENCE OF THE JAPANESE-UROLOGICAL-CANCER-RESEARCH-GROUP-FOR-ADRIAMYCIN [J].

AKAZA, H ;

KOISO, K ;

KOTAKE, T ;

MATSUMURA, Y ;

ISAKA, S ;

MACHIDA, T ;

OBATA, K ;

OHASHI, Y ;

OHE, H ;

OHI, Y ;

SHIMAZAKI, J ;

TASHIRO, K ;

UEDA, T ;

KAGAWA, S ;

NIIJIMA, T .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 30 :S15-S20

[3]

AKAZA H, 1987, CANCER CHEMOTH PHARM, V20, pS91

[4]

Akaza H, 1998, Urol Oncol, V4, P121, DOI 10.1016/S1078-1439(99)00015-0

[5] BCG immunotherapy of bladder cancer: 20 years on [J].

Alexandroff, AB ;

Jackson, AM ;

O'Donnell, MA ;

James, K .

LANCET, 1999, 353 (9165) :1689-1694

[6] Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study [J].

AliElDein, B ;

Nabeeh, A ;

ElBaz, M ;

Shamaa, S ;

Ashamallah, A .

BRITISH JOURNAL OF UROLOGY, 1997, 79 (05) :731-735

[7] Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): A randomized prospective study [J].

AlielDein, B ;

ElBaz, M ;

Aly, ANM ;

Shamaa, S ;

Ashamallah, A .

JOURNAL OF UROLOGY, 1997, 158 (01) :68-73

[8]

ASAHI T, 1980, ACTA MED OKAYAMA, V34, P43

[9] Pharmacologic effects of paclitaxel in human bladder tumors [J].

Au, JLS ;

Kalns, J ;

Gan, YB ;

Wientjes, MG .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 41 (01) :69-74

[10] Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial [J].

Au, JLS ;

Badalament, RA ;

Wientjes, MG ;

Young, DC ;

Warner, JA ;

Venema, PL ;

Pollifrone, DL ;

Harbrecht, JD ;

Chin, JL ;

Lerner, SP ;

Miles, BJ .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (08) :597-604

← 1 2 3 4 5 6 7 8 9 10 →